Martin Fellermeyer

@MFellermeyer

Final year PhD student focusing on cancer immunotherapy and antibody engineering @DavisLab_Oxford @UniofOxford.

가입일 Mart 2023

40 팔로잉31 팔로워

Martin Fellermeyer 리트윗함

MRC TIDU@MRC_TIDU·13 Şub

NEW: @ImmunityCP study from the @DavisLab_Oxford, @CornallLab and @KlenermanLab uncovers how antibodies trigger immune receptors & provides a framework for designing better therapeutic antibodies for cancer & autoimmune diseases. Read the full story here: bit.ly/498KFEB

English

6.3K

Martin Fellermeyer 리트윗함

Edward Jenkins@DrEdJenks·18 Tem

Got a big itch to study T-cell exhaustion!!?? Our review has got your back! We include: 🙆The latest updates in exhaustion🙆 🧪In vivo/vitro models of exhaustion🧪 📊How to best verify in vitro exhausted T cells📊 📈The future of in vitro approaches📈 doi.org/10.1093/oxfimm…

English

3.7K

Martin Fellermeyer@MFellermeyer·20 Haz

Thanks to the WIMM Postdoc Association for organising this symposium!

MRC WIMM@MRC_WIMM

Congratulations to the winners of the audience-voted awards at the @MRC_WIMM Postdoc Symposium yesterday: 🎉Best Scientific Report: Andrew McIntyre (@ChakravertyLab) 🌟Best Introductory Flash Talk: @MFellermeyer (@DavisLab_Oxford) ⚡️Runner Up: Li-Hsin Chang (@jdavieslab)

English

318

Martin Fellermeyer 리트윗함

Immunotherapy Advances Journal@IMTadvances·16 May

Researchers at @DavisLab_Oxford investigate the potential of a new combination #immunotherapy of #nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a #CD200R blocker Explore their results in mouse models for colorectal & lung #cancer ➡️bit.ly/3Madlmm

Immunotherapy Advances Journal tweet media

English

1.7K

Martin Fellermeyer@MFellermeyer·1 Nis

Very pleased to have my first PhD publication published in @IMTadvances. Using humanised mice we trialled the combination immunotherapy of nivolumab and OX108 (a CD200R blocker) in two tumour models. @DavisLab_Oxford @CornallLab @MRC_HIU @MRC_WIMM @RDMOxford

Immunotherapy Advances Journal@IMTadvances

Our latest article explores the potential of a combination #immunotherapy comprising #Nivolumab, a clinically approved #PD1 blocking antibody, & OX108, a CD200R antagonist, in mouse models for colorectal & lung #cancer Explore the results ➡️bit.ly/3nCdUwU

English

3.9K

탐색

@ImmunityCP @CornallLab @KlenermanLab @IMTadvances @MRC_WIMM @RDMOxford @elonmusk @BarackObama